Leadership Team

James Green is Chairman, President and Chief Executive Officer of Harvard Bioscience. He was named President and Chief Executive Officer in July 2019 and Chairman of the Board of Directors in June 2017. Green has been a member of the Company’s Board of Directors since April 2015. Green served as President and Chief Executive Officer of Analogic Corporation (NASDAQ: ALOG) from 2007 to 2016. While leading the public company through the great recession, Analogic’s core revenues grew over 50%, and gross margins, operating margins and earnings per share dramatically improved. Immediately prior to becoming President and Chief Executive Officer of Harvard Bioscience, Green served as President of Spacelabs Healthcare, where he led a successful global restructuring, rationalizing the company’s cost structure and product portfolio and quickly stabilized revenues while significantly improving operating margins. Earlier in his career, Green was Regional Vice President of a division of Quest Diagnostics Corporation, Sr. VP & General Manager of Koninklijke Philips Electronics NV Global Computed Tomography Business and held various leadership positions at St. Jude Medical Inc., Beckman Instruments, McDonnell Douglas Corporation and Northrop Advanced Systems. Green earned a bachelor’s degree in electrical engineering from the University of Missouri at Columbia and a master’s degree in computer engineering from the University of Southern California and is a graduate of the Stanford University Executive Program.

Mark Frost joined Harvard Bioscience as Interim CFO & Treasurer in 2025.   Mark brings over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to HBio since January 2025. Mark previously served as the Chief Financial Officer of Fathom (NYSE:FATH), a digital manufacturing company providing prototype and bridge production capability to accelerate new product development for Fortune 500 companies. Prior to joining Fathom, Mark served as Chief Financial Officer for Argon Medical Devices, a medical devices company planning to go public in Hong Kong. Prior to Argon, Mark was the Chief Financial Officer for three public Healthcare companies including Analogic (NASDAQ: ALOG), AngioDynamics (NASDAQ: ANGO) and AMRI (NASDAQ: AMRI). Mark began his career with General Electric (NYSE: GE), where he served in a variety of finance roles over a 14-year period.

Mark holds a BA in International Relations and Economics from Colgate University. He is also a graduate of the INSEAD Global Executive Program and GE Financial Management Program.

John Fry joined Harvard Bioscience as Chief Legal Counsel in 2022. He has over 15 years’ experience as a public company general counsel in the life science, medical imaging and security technology industries, having previously led the legal functions at Quanterix Corporation and Analogic Corporation. Earlier in his legal career, Fry served in private practice with a focus on business and technology law and as chief counsel for Philips Medical Systems’ global computed tomography business. Fry began his career as an electrical engineer and engineering manager. An advanced gas analyzer aimed at improving efficiency and reducing greenhouse gas emissions in power generation applications initially developed by Fry and his team remains in commercial production some 35 years after its launch. He is a named inventor on 10 United States patents.

Fry holds a juris doctor degree, summa cum laude, from Cleveland-Marshall College of Law as well as bachelor’s and master’s degrees in electrical engineering from Case Western Reserve University.

As the former Senior Director of Applications and Business Intelligence for Haemonetics, Diane has extensive experience transforming sales analytics and fleet management, in addition to leading a number of projects that resulted in significant cost reductions. Before joining the Harvard Bioscience family, Diane held leadership roles in both private and public companies, including Kaz, Paychex, and Oracle, and is proud to have spent half her career as a consultant leading small teams through significant systems changes for a wide range of businesses.

When she’s not transforming IT systems, Diane enjoys football, flowers, and food – spending fall weekends with her husband, Jay, at their son’s football games. She also prides herself on spending her spare time in the spring and summer working on 15 gardens and a one-acre yard, leaving any leftover spare time to her love of cooking.

Diane holds a bachelor’s degree in finance from the University of San Francisco.

As the advocate of internal culture and people operations, Lori has dedicated the last two-plus decades to Harvard Bioscience, advocating for continual improvement in her broad responsibilities in human resources and administration. Before joining Harvard Bioscience, Lori was a proud entrepreneur and independent business owner for 15 years, with extensive medical device experience with GV Medical and St. Jude Medical. Outside of work, Lori continues to hone her skills as a member of Toastmasters International, as well as being an active officer at P.E.O., a philanthropic organization for women.

Lori holds a business degree from the University of Phoenix.

Nitya Shetty joined Harvard Bioscience in October 2021 as Vice President, Global Research and Development. Before joining Harvard Bioscience, Nitya worked at Spacelabs Healthcare for 15 years, specializing in Patient Monitoring and GE Consumer & Industrial for seven years.

Nitya has experience in developing innovative and high-performance R&D onshore/ offshoring centers across the span of multiple geographies that are constantly evolving and supporting revenue generation.  He played a key role in transforming medical devices to catch up with the latest consumer technologies for patient comfort and simple product lifecycle management.

Nitya has been successful in developing joint ventures, partners, and acquisitions to keep up with fast-changing technology, and in delivering products that exceed customer expectations. He is experienced in building and managing strong teams in advanced research and development, integration and systems, and operations management.

Ryan Wallace was named Senior Vice President Global Sales, Preclinical Systems in April 2020, where he leads our global direct sales concentrating on the leading Clinical Research Organizations (CROs), pharmaceutical companies and certain strategic accounts.  Wallace joined the company in January 2020, bringing extensive leadership and strategic selling experience and large account management of healthcare Integrated Delivery Networks, including over a decade of consecutive year-over-year double digit growth. Immediately prior to joining Harvard Bioscience, Wallace was a sales leader and top performer with Spacelabs Healthcare where he amassed a wealth of experience in healthcare capital equipment and service sales. Wallace has a BBA from Texas Lutheran University in Marketing and Management.